相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。YAP promotes erlotinib resistance in human non-small cell lung cancer cells
Ping-Chih Hsu et al.
ONCOTARGET (2016)
YAP and the drug resistance highway
Alona Keren-Paz et al.
NATURE GENETICS (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Avnish Kapoor et al.
CELL (2014)
A Phase I/II Study Combining Erlotinib andDasatinib for Non-Small Cell Lung Cancer
Kathryn A. Gold et al.
ONCOLOGIST (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
Melissa L. Johnson et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer
Eric B. Haura et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung Cancer
Faye M. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
